Lacrimal Devices

Global Lacrimal Devices Market to Reach US$182.8 Million by 2030

The global market for Lacrimal Devices estimated at US$156.5 Million in the year 2024, is expected to reach US$182.8 Million by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Lacrimal Intubation Sets, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$49.3 Million by the end of the analysis period. Growth in the Lacrimal Tubes segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.6 Million While China is Forecast to Grow at 5.2% CAGR

The Lacrimal Devices market in the U.S. is estimated at US$42.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$35.6 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Lacrimal Devices Market – Key Trends & Drivers Summarized

Why Are Lacrimal Devices Gaining Prominence in Ophthalmic Treatments?

Lacrimal devices have become an essential component in modern ophthalmology, particularly for the treatment of dry eye syndrome, nasolacrimal duct obstruction (NLDO), and chronic epiphora (excessive tearing). These devices, including punctal plugs, lacrimal stents, and canalicular implants, are widely used in both minimally invasive and surgical interventions, offering effective solutions for tear drainage disorders. As the global prevalence of eye-related conditions continues to rise due to aging populations, increased screen exposure, and environmental pollutants, demand for lacrimal devices has surged across healthcare settings.

One of the key factors driving market growth is the increasing adoption of non-invasive and reversible treatments for dry eye syndrome. Punctal occlusion using silicone or collagen-based plugs has gained popularity as a first-line treatment, providing long-term relief without the need for prescription eye drops or surgical interventions. Moreover, advancements in lacrimal stenting and balloon catheter dilation have enabled more effective treatment of blocked tear ducts, reducing the need for complex surgeries. As ophthalmologists seek efficient and patient-friendly solutions for lacrimal disorders, lacrimal devices are expected to play an increasingly important role in clinical practice.

How Are Technological Innovations Enhancing Lacrimal Device Performance?

The lacrimal device market has witnessed significant technological advancements, particularly in the development of bioresorbable implants, smart punctal plugs, and laser-assisted lacrimal procedures. Bioresorbable lacrimal implants, made from biodegradable polymers, offer a temporary yet effective solution for tear drainage disorders, gradually dissolving over time without requiring removal. This innovation has provided an alternative to traditional silicone-based devices, particularly for patients seeking short-term treatment options.

Another key development in the market is the rise of smart punctal plugs embedded with drug-eluting capabilities. These devices not only retain tears but also deliver controlled doses of anti-inflammatory or lubricating agents, enhancing treatment efficacy for chronic dry eye patients. Additionally, laser-assisted lacrimal surgery has improved the precision of tear duct procedures, reducing recovery times and post-operative complications. The combination of digital diagnostics, AI-driven treatment planning, and minimally invasive lacrimal procedures has expanded treatment possibilities, making lacrimal devices more effective and accessible.

Is the Market Expanding Beyond Dry Eye Syndrome? Exploring New Applications

While lacrimal devices are predominantly used for dry eye syndrome and nasolacrimal duct obstruction, their applications are expanding into post-operative eye care, pediatric ophthalmology, and aesthetic treatments. In refractive surgery and cataract procedures, punctal occlusion is increasingly used to manage post-operative dry eye, improving patient comfort and surgical outcomes. Pediatric ophthalmologists are also utilizing lacrimal stents and balloon dilation techniques to treat congenital nasolacrimal duct obstruction, reducing the need for invasive surgery in infants.

Additionally, the rise of aesthetic ophthalmology has driven interest in lacrimal devices for cosmetic tear film management. Patients undergoing eyelid surgeries or botulinum toxin injections around the eyes often experience temporary tear film imbalances, making punctal plugs a useful adjunct treatment. As the demand for minimally invasive ophthalmic procedures grows, lacrimal devices are finding new applications beyond traditional eye care, broadening their market potential.

What Are the Key Growth Drivers Fueling the Lacrimal Devices Market?

The growth in the lacrimal devices market is driven by several factors, including increasing cases of dry eye syndrome, advancements in minimally invasive ophthalmic treatments, rising adoption of drug-eluting implants, and the growing geriatric population. One of the primary market drivers is the widespread prevalence of digital eye strain and environmental factors contributing to tear film dysfunction. As more individuals experience chronic dryness due to prolonged screen use, the demand for punctal plugs and tear retention devices has increased significantly.

Another major growth driver is the expansion of ophthalmic surgical procedures, including LASIK, cataract surgeries, and oculoplastic interventions, which frequently require post-operative tear management. The shift toward non-invasive and office-based procedures has also fueled the adoption of lacrimal stents and balloon catheters, reducing the burden of hospital-based surgeries. Additionally, the increasing availability of bioresorbable lacrimal implants and combination therapy devices has attracted interest from both patients and healthcare providers.

The integration of digital health technologies and AI-driven diagnostics in ophthalmology has further contributed to market expansion. Automated tear film analyzers and predictive analytics are improving the identification of lacrimal disorders, enabling early interventions with lacrimal devices. Furthermore, the rise of telemedicine and remote eye care has enhanced accessibility to lacrimal treatments, particularly in underserved regions. As ophthalmic innovations continue to evolve, the lacrimal devices market is expected to witness sustained growth, driven by increasing patient awareness, technological advancements, and the rising prevalence of eye disorders.

SCOPE OF STUDY:

The report analyzes the Lacrimal Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Lacrimal Intubation Sets, Lacrimal Tubes, Lacrimal Stents, Lacrimal Cannula & Spatula, Lacrimal Dilator, Lacrimal Punctal Plugs, Other Lacrimal Products); End-Use (Hospitals End-Use, Ophthalmic Clinics End-Use, Diagnostic Centers End-Use, Other End-Uses); Application (Dry Eye Application, Glaucoma Application, Epiphora Application, Drainage Obstruction Application, Lacrimal Gland Inflammation Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Alcon Inc.
• Bausch + Lomb Incorporated
• Bess Medizintechnik GmbH
• Braintree Scientific
• BVI (Beaver-Visitec International)
• Carl Zeiss Meditec AG
• EssilorLuxottica SA
• FCI Ophthalmics
• Gunther Weiss Scientific Glass
• HAAG-Streit Group
• Hoya Corporation
• JEDMED Instrument Company
• Johnson & Johnson Vision
• Kaneka Corporation
• Lacrimedics Inc
• Medennium
• Nidek Co. Ltd.
• Rumex International Co
• Topcon Corporation
• Walsh Medical Devices Inc

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.